<DOC>
	<DOCNO>NCT02928029</DOCNO>
	<brief_summary>This study conduct 2 part . The phase 1b part international , phase 1b , open-label , dose-escalation assessment radium-223 dichloride administer bortezomib dexamethasone subject relapse multiple myeloma . The primary endpoint determine optimal dose radium-223 dichloride combination bortezomib/dexamethasone Phase 2 portion study . The phase 2 part international , phase 2 , double-blind , randomize , placebo-controlled assessment radium-223 dichloride versus placebo administer bortezomib dexamethasone , subject relapse multiple myeloma . Up approximately 30 total subject dose cohort combine treated phase 1b part study approximately 196 subject enrol phase 2 part study .</brief_summary>
	<brief_title>Study Testing Radium-223 Dichloride Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Subject must document monoclonal plasma cell define institutional standard bone marrow &gt; =10 % point disease history presence biopsy proven plasmacytoma Subjects must receive least 1 3 previous line treatment response treatment ( i.e. , achieve minimal response [ MR ] better ) accord International Myeloma Working Group ( IMWG ) uniform response criterion Subject must nonrefractory bortezomib another proteasome inhibitor ( PI ) , like ixazomib carfilzomib ( Refractory define : progression disease receive bortezomib therapy within 60 day end bortezomib therapy another PI therapy , like ixazomib carfilzomib ) Subjects must progressive disease accord IMWG uniform response criterion follow last multiple myeloma treatment Subjects must measurable disease define least 1 follow ( accord central laboratory result ) : Serum Mprotein ≥1 g/dL define follow : IgG multiple myeloma : Serum monoclonal paraprotein ( M protein ) level ≥1.0 g/dL IgA , IgD , IgE , IgM multiple myeloma : serum Mprotein level ≥0.5 g/dL Urine Mprotein ≥200 mg/24 hour ( immunoglobulin heavy chain type ) Serum free light chain ( FLC ) ≥10 mg/dL abnormal ratio ≥1 bone lesion identifiable radiograph , compute tomography , positron emission tomography compute tomography ( PET CT ) , magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 Adequate hepatic function , bilirubin ≤1.5 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤3.0 x ULN Absolute neutrophil count ( ANC ) ≥1.5 × 10e9/L , hemoglobin ( Hb ) ≥9.0 g/dL , platelet count ≥75.0 × 10e9/L independent transfusion red blood cell ( RBC ) platelet concentrate independent granulocyte colony stimulate factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) International normalize ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 1.5 x ULN . PT use instead INR ≤ 1.5 x ULN Systemic glucocorticoid therapy ( prednisone &gt; 10 mg/day orally equivalent ) within last 4 week prior first dose , unless taper stable dose ( prednisone ≤10 mg/day orally equivalent ) least 1 week Subjects know POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) light chain ( AL ) amyloidosis Plasma cell leukemia Subject receive antimyeloma treatment within 2 week 5 pharmacokinetic halflives treatment , whichever longer , date randomization . A list antimyeloma treatment correspond pharmacokinetic halflives provide Site Investigational Product Procedures Manual ( IPPM ) . Radiation therapy previous 4 week prior first dose except give pain management involve less 10 % bone marrow Prior treatment radium223 dichloride experimental radiopharmaceutical Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , symptomatic cardiac ischemia , cardiomyopathy , clinically relevant ventricular arrhythmia , pericardial disease , unstable angina myocardial infarct previous 6 month prior first dose , leave ventricular ejection fraction &lt; 40 % Neuropathy ≥ Grade 2 Grade 1 pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radium-223 dichloride</keyword>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>early relapse multiple myeloma</keyword>
	<keyword>combination therapy multiple myeloma</keyword>
</DOC>